BioNote (A377740) Stock Overview
Manufactures and sells in-vitro diagnostic animal medicines in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
A377740 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeBioNote, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,050.00 |
| 52 Week High | ₩6,320.00 |
| 52 Week Low | ₩4,435.00 |
| Beta | 0.82 |
| 1 Month Change | 0.60% |
| 3 Month Change | -12.48% |
| 1 Year Change | 10.26% |
| 3 Year Change | -15.83% |
| 5 Year Change | n/a |
| Change since IPO | -52.58% |
Recent News & Updates
Recent updates
BioNote's (KRX:377740) Performance Is Even Better Than Its Earnings Suggest
Nov 25
BioNote's (KRX:377740) Performance Is Even Better Than Its Earnings Suggest
May 26BioNote's (KRX:377740) Strong Earnings Are Of Good Quality
Nov 24BioNote, Inc.'s (KRX:377740) 38% Price Boost Is Out Of Tune With Earnings
Aug 16There May Be Some Bright Spots In BioNote's (KRX:377740) Earnings
May 25Shareholder Returns
| A377740 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.3% | -4.1% | 1.6% |
| 1Y | 10.3% | 35.4% | 147.0% |
Return vs Industry: A377740 underperformed the KR Biotechs industry which returned 35.4% over the past year.
Return vs Market: A377740 underperformed the KR Market which returned 147% over the past year.
Price Volatility
| A377740 volatility | |
|---|---|
| A377740 Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in KR Market | 16.2% |
| 10% least volatile stocks in KR Market | 4.7% |
Stable Share Price: A377740 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A377740's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | n/a | www.bionote.co.kr |
BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea. It offers animal diagnostics products, such as fluorescence immunoassay, molecular diagnostics, clinical biochemistry, rapid immunoassay, and enzyme-linked immunosorbent assay products. The company also provides bio-content products, including rapid immunoassay for humans, human intermediate goods, and bio-contents reagents.
BioNote, Inc. Fundamentals Summary
| A377740 fundamental statistics | |
|---|---|
| Market cap | ₩510.21b |
| Earnings (TTM) | -₩87.50b |
| Revenue (TTM) | ₩118.32b |
Is A377740 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A377740 income statement (TTM) | |
|---|---|
| Revenue | ₩118.32b |
| Cost of Revenue | ₩52.65b |
| Gross Profit | ₩65.68b |
| Other Expenses | ₩153.17b |
| Earnings | -₩87.50b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -866.05 |
| Gross Margin | 55.51% |
| Net Profit Margin | -73.95% |
| Debt/Equity Ratio | 0% |
How did A377740 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/04 21:49 |
| End of Day Share Price | 2026/05/04 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioNote, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.